Vasopressin as an adjunct therapy for pulmonary hypertension: A case report

Andra Malikiwi; Arun Sasi; Kenneth Hark Hong Tan; Arvind Sehgal

doi:10.1007/s00431-013-2225-y

Vasopressin as an adjunct therapy for pulmonary hypertension: A case report

Andra Malikiwi, Arun Sasi, Kenneth Hark Hong Tan, Arvind Sehgal

Paediatrics Monash Health

Research output: Contribution to journal › Article › Other › peer-review

12 Citations (Scopus)

Abstract

UNLABELLED: Vasopressin is emerging as a therapeutic adjunct option towards treatment of shock states in the pediatric population. Its effects on pulmonary vasculature are less well understood. This report describes a 5-month-old infant with nitric oxide-unresponsive pulmonary hypertension, oxygenation failure, and systemic hypotension. Vasopressin therapy improved oxygenation and blood pressure and biventricular function, allowing weaning of nitric oxide and inotropic support. No decrease in coronary flow was noted.

CONCLUSIONS: Vasopressin could be considered as an adjunct option in infants with pulmonary hypertension and systemic hypotension. Echocardiographic monitoring during treatment is recommended.

Original language	English
Pages (from-to)	1651-1654
Number of pages	4
Journal	European Journal of Pediatrics
Volume	173
Issue number	12
DOIs	https://doi.org/10.1007/s00431-013-2225-y
Publication status	Published - 1 Dec 2014

Access to Document

10.1007/s00431-013-2225-y

Cite this

@article{82eb0ebed44b40748ab14c98d58f5605,

title = "Vasopressin as an adjunct therapy for pulmonary hypertension: A case report",

abstract = "UNLABELLED: Vasopressin is emerging as a therapeutic adjunct option towards treatment of shock states in the pediatric population. Its effects on pulmonary vasculature are less well understood. This report describes a 5-month-old infant with nitric oxide-unresponsive pulmonary hypertension, oxygenation failure, and systemic hypotension. Vasopressin therapy improved oxygenation and blood pressure and biventricular function, allowing weaning of nitric oxide and inotropic support. No decrease in coronary flow was noted.CONCLUSIONS: Vasopressin could be considered as an adjunct option in infants with pulmonary hypertension and systemic hypotension. Echocardiographic monitoring during treatment is recommended.",

author = "Andra Malikiwi and Arun Sasi and Tan, {Kenneth Hark Hong} and Arvind Sehgal",

year = "2014",

month = dec,

day = "1",

doi = "10.1007/s00431-013-2225-y",

language = "English",

volume = "173",

pages = "1651--1654",

journal = "European Journal of Pediatrics",

issn = "0340-6199",

publisher = "Springer",

number = "12",

}

TY - JOUR

T1 - Vasopressin as an adjunct therapy for pulmonary hypertension

T2 - A case report

AU - Malikiwi, Andra

AU - Sasi, Arun

AU - Tan, Kenneth Hark Hong

AU - Sehgal, Arvind

PY - 2014/12/1

Y1 - 2014/12/1

N2 - UNLABELLED: Vasopressin is emerging as a therapeutic adjunct option towards treatment of shock states in the pediatric population. Its effects on pulmonary vasculature are less well understood. This report describes a 5-month-old infant with nitric oxide-unresponsive pulmonary hypertension, oxygenation failure, and systemic hypotension. Vasopressin therapy improved oxygenation and blood pressure and biventricular function, allowing weaning of nitric oxide and inotropic support. No decrease in coronary flow was noted.CONCLUSIONS: Vasopressin could be considered as an adjunct option in infants with pulmonary hypertension and systemic hypotension. Echocardiographic monitoring during treatment is recommended.

AB - UNLABELLED: Vasopressin is emerging as a therapeutic adjunct option towards treatment of shock states in the pediatric population. Its effects on pulmonary vasculature are less well understood. This report describes a 5-month-old infant with nitric oxide-unresponsive pulmonary hypertension, oxygenation failure, and systemic hypotension. Vasopressin therapy improved oxygenation and blood pressure and biventricular function, allowing weaning of nitric oxide and inotropic support. No decrease in coronary flow was noted.CONCLUSIONS: Vasopressin could be considered as an adjunct option in infants with pulmonary hypertension and systemic hypotension. Echocardiographic monitoring during treatment is recommended.

UR - http://www.scopus.com/inward/record.url?scp=84937511538&partnerID=8YFLogxK

U2 - 10.1007/s00431-013-2225-y

DO - 10.1007/s00431-013-2225-y

M3 - Article

C2 - 24297672

SN - 0340-6199

VL - 173

SP - 1651

EP - 1654

JO - European Journal of Pediatrics

JF - European Journal of Pediatrics

IS - 12

ER -

Vasopressin as an adjunct therapy for pulmonary hypertension: A case report

Abstract

Access to Document

Other files and links

Cite this